Boulevard Bio Launches with $65 Million
Boulevard Bio emerged from stealth with approximately $65 million in aggregate equity and convertible-note financing from Deerfield and affiliates. Its precision-immunology pipeline includes BLVD101, a dual BAFF/APRIL antibody with interim single-dose healthy-volunteer pharmacology supporting…
